GRAIL, Inc. is a commercial-stage healthcare company that provides multi-cancer early detection testing and services in the United States and internationally. Its offerings include Galleri, a cancer screening test for asymptomatic individuals over 50, and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides development services such as support for clinical studies, pilot testing, research, and therapy development. Its precision oncology portfolio includes an RUO-targeted methylation-based platform for applications in disease prognostication, risk stratification, minimal residual disease detection, and recurrence and relapse monitoring. GRAIL was incorporated in 2015 and is headquartered in Menlo Park, California.
GRAIL Hit by Multiple Securities Fraud Lawsuits Over Failed NHS-Galleri Trial
▼
Securities Fraud Class Action Filed A class action lawsuit accuses GRAIL and executives of misleading investors about the NHS-Galleri trial's ability to meet its goal. This legal fight could lead to fines or payouts, weighing on the stock.
This is the first major lawsuit this period and directly threatens GRAIL's finances and reputation.
▼
More Law Firms Join with Similar Suits Bronstein, Faruqi, Pomerantz, and Moore Law have all filed or announced investigations, each reminding investors of the August 4 deadline. The growing number of claims raises the potential legal costs and keeps negative attention on GRAIL.
Shows the legal pressure is widening, not just a single firm, which increases uncertainty for the stock.
◆
Galleri Misses Trial Goal but Still Pursues FDA Approval The Galleri test failed to reduce late-stage cancers in a large NHS trial, but GRAIL is still seeking FDA approval and insurance coverage. Management points to positive trends in 12 deadly cancers, which could support future revenue if insurers agree.
This is the core clinical setback that triggered the lawsuits, but also the only potential positive path forward.
Latest
▲2▼1
FDA Panel Backs Galleri, but Securities Fraud Lawsuits Loom
▲
FDA Panel Endorses Galleri On September 24, an FDA advisory panel voted 6-4 that Galleri is effective, 10-0 safe, and 7-2 benefits outweigh risks. This clears a major hurdle toward FDA approval, expected early 2027, which would open Medicare and private insurance coverage and boost future sales.
This is the biggest new positive catalyst, directly advancing the path to insurance coverage and revenue growth.
▲
Strong Q2 Galleri Volume and Revenue Growth GRAIL reported Q2 2026 Galleri test volume up 35% to over 61,000 and revenue up 24% to $42.6 million. Total revenue rose 26% to $44.7 million, and a $110 million equity investment from Samsung strengthened the balance sheet, showing growing demand and financial backing.
This new data confirms commercial momentum and cash strength, supporting the stock's fundamental value.
▼
Securities Fraud Lawsuits Over Trial Disclosures Multiple law firms filed or reminded investors of a securities class action alleging GRAIL misled investors about the NHS-Galleri trial's likelihood of success. The August 4 lead plaintiff deadline passed, but the lawsuit continues, creating legal overhang and potential financial penalties that could weigh on the stock.
This is a new legal development that adds uncertainty and potential costs, a real counterweight to the positive news.
Q3 2026
▲2▼1
FDA Panel Backs Galleri, but Fraud Lawsuits Loom
▲
FDA Panel Endorses Galleri An FDA advisory panel voted 6-4 that Galleri is effective, 10-0 safe, and 7-2 that benefits outweigh risks. This clears a major hurdle toward expected early-2027 approval and potential Medicare and private insurance coverage.
This is the biggest new positive catalyst that could drive future revenue and stock price.
▲
Strong Sales and Samsung Investment Q2 Galleri volume rose 35% to over 61,000 tests, revenue grew 24% to $42.6 million, and total revenue rose 26% to $44.7 million. Samsung's $110 million equity investment strengthened the balance sheet.
These new financial and strategic developments show improving business performance and cash position.
▼
Securities Fraud Lawsuits Pile Up Lawsuits over alleged misstatements about the failed NHS-Galleri trial kept accumulating, raising legal costs and negative attention. The August 4 lead plaintiff deadline sustained pressure, creating a legal overhang that could weigh on the stock.
This ongoing legal risk is a key negative factor that could result in penalties and distract management.
News & notes movingGRAL
United States
Biotech & Genomic Medicine▲
Jim Cramer Says GRAIL Could Rise Like Moderna After FDA Panel Backs Galleri
Jim Cramer said GRAIL, Inc. could climb much higher after an FDA advisory panel backed its Galleri multi-cancer early detection test, comparing the stock to Moderna when it traded around $120. The panel voted 7-2 with one abstention that Galleri's benefits outweighed its risks, 6-4 on effectiveness and unanimously on safety, though the recommendation is not binding and final approval had not been granted as of October 2, with Reuters reporting a decision is expected in the coming months. GRAIL generated $44.7 million of revenue in the second quarter, up 26% year over year, as Galleri revenue rose 24% to $42.6 million and test volume increased 35% to more than 61,000, while the company posted a $110.2 million net loss and a $90.3 million adjusted EBITDA loss with $861.6 million in cash, cash equivalents and short-term marketable securities at June 30. Moderna, Inc. reported $145 million of revenue in the second quarter against $142 million a year earlier and a $782 million net loss, ending June with $6.9 billion in cash, cash equivalents and investments, and its Phase 3 INTerpath-001 trial of intismeran autogene with Merck's Keytruda met its recurrence-free-survival and distant-metastasis-free-survival endpoints in resected melanoma. Citi analyst Geoff Meacham said on September 30 that Moderna's roughly $80 billion market capitalization was approaching Regeneron's despite materially lower expected revenue and earnings, while GRAIL's bear case rests on adoption and reimbursement, with Galleri costing about $700 out of pocket and generally not covered by Medicare or private insurers.
Biotech & Genomic Medicine › Diagnostics & Precision Testing ▲Regulation
Biotech & Genomic Medicine › Tools, Diagnostics & CDMO ▲Regulation
GRAL · Regulation · Positive FDA advisory panel voted 7-2 that Galleri's benefits outweigh risks, advancing it toward approval.
MRNA · Capital · Neutral Cramer compared GRAIL to Moderna at $120, while Citi noted Moderna's ~$80B market cap approaches Regeneron's despite lower expected revenue and earnings.
GRAIL's Galleri Wins Favorable FDA Panel Vote After Strong PATHFINDER 2 Data
GRAIL announced in September 2026 that its Galleri multi-cancer early detection blood test showed strong performance in the PATHFINDER 2 study and received a favorable U.S. FDA advisory committee vote supporting its safety, benefit-risk profile and effectiveness for use alongside standard screening in adults aged 50 and older. The PATHFINDER 2 data indicated that adding Galleri increased cancers detected through screening more than six-fold with a very low false-positive rate, while the test also accurately pointed doctors to the likely cancer origin in over nine out of ten positive cases. The advisory committee's favorable vote and the PATHFINDER 2 results reinforce the core near-term catalyst around potential PMA approval and payer coverage, though GRAIL's high cash burn and lack of profitability remain the biggest risk. GRAIL's narrative projects $348.4 million revenue and $60.1 million earnings by 2029, with a $97.40 fair value implying a 32% downside to its current price, while some of the lowest estimate analysts were assuming only about US$277.6 million of revenue and a small US$49.4 million profit by 2029.
FDA Panel Backs GRAIL's Galleri Multi-Cancer Blood Test
A panel of US FDA advisors voted 6-4 that there is reasonable evidence GRAIL's multi-cancer early detection blood test Galleri is effective. Members of the Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee also voted 10-0 that the test is safe and 7-2 with one abstention that its benefits outweigh the risks, which include false positive or negative readings. Panel member Victor van Berkel of University of Louisville Physicians said that if more early-stage cancers can be found in the population that cannot currently be screened for, that will end up having benefit, though some members noted the test should be used in addition to current cancer screening methods rather than as a replacement. While Galleri is currently available in the US through cash payment, approval would mean coverage by Medicare and private insurance. A decision from the FDA is expected in the first part of 2027.
Biotech & Genomic Medicine › Diagnostics & Precision Testing ▲Regulation
GRAL · Regulation · Positive FDA advisory panel voted that GRAIL's Galleri multi-cancer blood test is effective, safe, and benefits outweigh risks, advancing it toward FDA approval and Medicare/private insurance coverage.
GRAIL's Galleri MCED Test Gets FDA Advisory Panel Review Date
GRAIL announced that the FDA's Molecular and Clinical Genetics Panel will review its Premarket Approval application for the Galleri multi-cancer early detection blood test on September 23, 2026. Galleri detects cancer-specific methylation patterns across multiple cancer types before symptoms appear and is intended to complement existing screenings. The submission includes data from the PATHFINDER 2 study of 25,490 participants and the NHS-Galleri trial of over 70,000 participants. GRAIL noted that 70-80% of cancer deaths occur from cancers without standard screening options. The stock closed Friday at $69.48, up 9.59%.
GRAIL Inc reported second-quarter 2026 total revenue of $44.7 million, a 26% increase year over year, driven by a 35% jump in Galleri test volumes to over 61,000 tests. However, the primary endpoint of the NHS Galleri trial—a combined reduction of stage III and IV cancers—was not met, and the company expects the FDA to convene an advisory committee in the fall, adding uncertainty to the approval timeline currently anticipated for early 2027. Screening revenue reached $42.6 million, up 24%, while development services revenue contributed $2 million. Net loss narrowed 3% to $110.2 million, and non-GAAP adjusted gross profit rose 34% to $21.6 million, though adjusted EBITDA loss widened 15% to negative $90.3 million. GRAIL ended the quarter with $861.6 million in cash, including a $110 million strategic investment from Samsung, and announced a new collaboration with Priority Health to expand employer group coverage for the Galleri test.
Hagens Berman Files Securities Fraud Class Action Against GRAIL Over NHS-Galleri Trial Disclosures
Hagens Berman Sobol Shapiro LLP has filed a securities fraud class action lawsuit against GRAIL, Inc. and is urging investors who suffered substantial losses to seek lead plaintiff status by the August 4, 2026 deadline. The lawsuit alleges that GRAIL and certain senior executives misled investors about the clinical design and efficacy of its NHS-Galleri cancer screening trial, claiming the three-year follow-up period was sufficient to show a statistically significant reduction in late-stage cancer diagnoses while concealing internal indicators that a longer timeline was needed. On February 19, 2026, GRAIL disclosed that the trial failed to meet its primary endpoint and admitted it probably should have allowed for a longer follow-up period, causing shares to plummet 50.55% from $101.53 to $50.21 in a single session and erasing over $2.2 billion in market capitalization. The firm is also investigating when management first recognized the divergence from the touted three-year duration, and encourages whistleblowers with non-public information to come forward.
GRAL · Regulation · Negative Securities fraud class action lawsuit filed against GRAIL over misleading disclosures about NHS-Galleri trial, causing shares to plummet.
Law Offices of Howard G. Smith Reminds Investors of Lead Plaintiff Deadlines in Securities Fraud Class Actions Against BMI, PICS, VRRM, and GRAL
The Law Offices of Howard G. Smith reminds investors that securities fraud class action lawsuits have been filed against Badger Meter, PicS N.V., Verra Mobility Corporation, and Grail, Inc., with lead plaintiff deadlines approaching in early August 2026. The Badger Meter suit, with a deadline of August 3, 2026, alleges the company concealed weakening demand by pulling forward customer orders to recognize revenue early. The PicS N.V. action, deadline August 4, 2026, claims the company's IPO offering documents failed to disclose deficient credit evaluation procedures and a reclassification of approximately R$590 million of exposures, leading to an incremental expected credit loss charge of R$88 million. Verra Mobility, also with an August 4 deadline, is accused of misleading investors about its reliance on a contract extension with Avis Budget for continued growth. Grail, Inc., with the same August 4 deadline, allegedly misrepresented the sufficiency of data from its trial's first screening round and Pathfinder studies to demonstrate the achievability of a primary endpoint. Investors who suffered losses can contact the firm to discuss their legal rights.
BMI · Demand · Negative Allegedly concealed weakening demand by pulling forward customer orders to recognize revenue early.
GRAL · Regulation · Negative Allegedly misrepresented sufficiency of trial data to demonstrate achievability of primary endpoint.
PICS · Capital · Negative IPO documents allegedly failed to disclose deficient credit evaluation procedures and reclassification leading to credit loss charge.
VRRM · Demand · Negative Allegedly misled investors about reliance on Avis Budget contract extension for continued growth.
Bragar Eagel & Squire Reminds GRAIL Investors of August 4 Lead Plaintiff Deadline
Bragar Eagel & Squire, P.C. reminds investors that a class action lawsuit has been filed against GRAIL, Inc. and that the deadline to seek lead plaintiff appointment is August 4, 2026. The lawsuit, filed in the United States District Court for the Northern District of California, covers purchasers of GRAIL common stock between May 13, 2025 and February 19, 2026. The complaint alleges that defendants made materially false and misleading statements and concealed adverse facts about the NHS Galleri trial, including that the trial period was insufficient to demonstrate the primary endpoint of a statistically significant reduction in Stage III-IV cancers. On February 19, 2026, GRAIL announced that the primary endpoint was not observed, causing its stock price to fall significantly. Investors who suffered losses can contact the firm's partners Brandon Walker or Melissa Fortunato at (212) 355-4648 or investigations@bespc.com.
Holzer & Holzer Reminds Investors of August 4 Deadline in Grail Securities Class Action
Holzer & Holzer, LLC reminds investors of the August 4, 2026 lead plaintiff deadline in a securities class action against Grail, Inc. The lawsuit alleges that Grail made false and misleading statements about the probability of achieving the primary endpoint in its NHS-Galleri trial. Shareholders who purchased Grail shares between May 13, 2025 and February 19, 2026 and suffered losses may contact the firm to discuss their legal rights.
Robbins Geller Announces August 4 Deadline for Grail Class Action Lead Plaintiff
Robbins Geller Rudman & Dowd LLP announced that investors who purchased Grail common stock between May 13, 2025 and February 19, 2026 have until Tuesday, August 4, 2026 to seek appointment as lead plaintiff in a securities class action lawsuit against the company. The lawsuit alleges that Grail and certain executives made false or misleading statements about the likelihood of achieving the primary endpoint in its NHS-Galleri cancer screening trial, concealing adverse facts that reduced the probability of success. On February 19, 2026, Grail disclosed that the trial did not meet its primary endpoint of a statistically significant reduction in late-stage cancers, causing its stock price to drop more than 50%. The case, captioned Robbins v. Grail, Inc., was filed in the Northern District of California under the Securities Exchange Act of 1934.
GRAIL investors face August 4, 2026 deadline to join securities class action
Bernstein Liebhard LLP reminds GRAIL, Inc. investors that the deadline to join a securities fraud class action lawsuit is August 4, 2026. The lawsuit, filed on behalf of investors who purchased or acquired GRAIL common stock between May 13, 2025 and February 19, 2026, alleges that the company and certain senior officers made materially false and misleading statements about its business operations, growth prospects, and financial stability, causing shares to trade at artificially inflated prices. Investors who suffered losses are encouraged to submit a form or contact Investor Relations Manager Peter Allocco before the deadline. Those wishing to serve as lead plaintiff must file papers by August 4, 2026, though participation in any recovery does not require serving as lead plaintiff.
Hagens Berman files securities fraud class action against GRAIL over NHS-Galleri trial disclosures
Hagens Berman Sobol Shapiro LLP has filed a securities fraud class action lawsuit against GRAIL, Inc., alleging the company misled investors about the design and efficacy of its NHS-Galleri cancer screening trial. The suit covers investors who purchased GRAIL common stock between May 13, 2025 and February 19, 2026, with a lead plaintiff deadline of August 4, 2026. The complaint claims GRAIL and senior executives touted a three-year follow-up period as sufficient to show a statistically significant reduction in late-stage cancer diagnoses, while concealing internal indicators that a longer timeline was needed. On February 19, 2026, GRAIL disclosed the trial failed to meet its primary endpoint and admitted it probably should have allowed for a longer follow-up, causing shares to plummet 50.55% from $101.53 to $50.21 in a single session and erasing over $2.2 billion in market capitalization. Hagens Berman is also investigating when management first knew the three-year timeline was inadequate.
Rosen Law Firm Reminds GRAIL Investors of August 4 Lead Plaintiff Deadline
Rosen Law Firm reminds purchasers of GRAIL, Inc. common stock during the class period from May 13, 2025 to February 19, 2026 of the August 4, 2026 lead plaintiff deadline in a securities class action. If you purchased GRAIL common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The lawsuit alleges that defendants made materially false and misleading statements and concealed adverse facts about the NHS-Galleri trial, including that the trial period was insufficient to demonstrate a reduction in Stage III-IV cancers. Investors with losses exceeding $100,000 are encouraged to secure counsel before the deadline. More information is available at rosenlegal.com.
GRAL · Regulation · Negative Securities class action lawsuit alleging false statements about NHS-Galleri trial, with lead plaintiff deadline approaching.
Bragar Eagel & Squire Reminds GRAIL Investors of August 4 Lead Plaintiff Deadline
Bragar Eagel & Squire, P.C. reminds investors that a class action lawsuit has been filed against GRAIL, Inc. and that the deadline to seek lead plaintiff appointment is August 4, 2026. The lawsuit, filed in the United States District Court for the Northern District of California, covers purchasers of GRAIL common stock between May 13, 2025 and February 19, 2026. The complaint alleges that defendants made materially false and misleading statements and concealed adverse facts about the NHS Galleri trial, including that the trial period was insufficient to demonstrate a reduction in Stage III-IV cancers. On February 19, 2026, GRAIL announced that the primary endpoint of statistically significant Stage III-IV reduction was not observed, causing the stock price to fall significantly. Investors who suffered losses can contact the firm's partners Brandon Walker or Melissa Fortunato at (212) 355-4648 or investigations@bespc.com.
Biotech & Genomic Medicine › Diagnostics & Precision Testing ▼Regulation
GRAL · Regulation · Negative Class action lawsuit alleging false statements about NHS Galleri trial results, with stock price drop after trial failure announced.
Grail investors face August 4 deadline to seek lead plaintiff in securities fraud suit
Glancy Prongay Wolke & Rotter LLP reminds Grail, Inc. shareholders of an August 4, 2026 deadline to move for lead plaintiff in a class action covering purchases of Grail common stock between May 13, 2025 and February 19, 2026. The suit follows Grail's February 19, 2026 disclosure that its NHS-Galleri Trial did not meet the primary endpoint of statistically significant Stage III-IV cancer reduction, partly because longer follow-up may be needed. On that news, Grail's stock fell $51.32, or 50.5%, to close at $50.21 per share on February 20, 2026. The complaint alleges that defendants made materially false or misleading statements and failed to disclose that management's confidence in earlier positive top-line results ignored trendlines suggesting three years would be insufficient to demonstrate the primary endpoint.
Holzer & Holzer Announces Lead Plaintiff Deadlines for Class Actions Against Badger Meter, Grail, and Verra Mobility
Holzer & Holzer, LLC has announced upcoming deadlines for investors to seek lead plaintiff appointment in shareholder class action lawsuits against Badger Meter, Grail, and Verra Mobility. The Badger Meter lawsuit covers purchases between April 18, 2024 and April 16, 2026, with a lead plaintiff deadline of August 3, 2026. The Grail lawsuit covers purchases between May 13, 2025 and February 19, 2026, and the Verra Mobility lawsuit covers purchases between February 24, 2026 and May 26, 2026, both with a lead plaintiff deadline of August 4, 2026. Investors who suffered losses are encouraged to contact the firm.
Hagens Berman Probes GRAIL Over Failed NHS-Galleri Trial Disclosures
National shareholder rights firm Hagens Berman is investigating claims in a pending securities class action against GRAIL, Inc. alleging the company misled investors about the clinical design and efficacy of its NHS-Galleri cancer screening trial. The lawsuit, covering a class period from May 13, 2025 to February 19, 2026, contends GRAIL concealed that its three-year follow-up period was insufficient to meet the primary endpoint of a statistically significant reduction in late-stage cancer diagnoses. On February 19, 2026, GRAIL disclosed the trial failed that endpoint and admitted it probably should have allowed a longer follow-up, causing shares to drop approximately 50.55% and erasing over $2.2 billion in market capitalization. Investors who suffered substantial losses have until August 4, 2026 to seek lead plaintiff appointment.
GRAIL shareholders face August 4 lead plaintiff deadline in securities class action
The Gross Law Firm has issued a shareholder alert for GRAIL, Inc., setting an August 4, 2026 deadline for investors to seek lead plaintiff appointment in a securities class action. The class period runs from May 13, 2025 to February 19, 2026, covering allegations that the company made false and misleading statements about its NHS-Galleri trial. On February 19, 2026, GRAIL announced the trial's primary endpoint of a statistically significant reduction in Stage III-IV cancers was not observed, causing its stock to plummet from $101.53 to $50.21 per share in a single day, a decline of about 50.55%. Shareholders who purchased GRAL shares during the class period are encouraged to register for the action, with no cost or obligation to participate.
Law Offices of Howard G. Smith Reminds Investors of Lead Plaintiff Deadlines in Securities Fraud Class Actions Against Badger Meter, PicS, Verra Mobility, and Grail
The Law Offices of Howard G. Smith reminds investors that securities fraud class action lawsuits have been filed against Badger Meter, PicS N.V., Verra Mobility Corporation, and Grail, Inc., with lead plaintiff deadlines approaching in early August 2026. For Badger Meter, the class period runs from April 18, 2024 to April 16, 2026, and the deadline is August 3, 2026; the complaint alleges the company pulled forward customer orders to recognize revenue early, concealing weakening demand. PicS N.V., whose class period covers its January 2026 IPO, faces an August 4, 2026 deadline, with allegations that offering documents failed to disclose deficient credit evaluation procedures and a reclassification of approximately R$590 million of exposures leading to an incremental expected credit loss charge of R$88 million. Verra Mobility's class period spans February 24, 2026 to May 26, 2026, with an August 4, 2026 deadline, and the complaint claims the company's growth outlook was dependent on a contract extension with Avis Budget while minimizing risks of replacement. Grail, Inc.'s class period is May 13, 2025 to February 19, 2026, also with an August 4, 2026 deadline, and the suit alleges management misplaced confidence in trial results and ignored data suggesting the primary endpoint might not be met. Investors who suffered losses can contact the firm to discuss their legal rights.
GRAL · Technology · Negative Allegedly management misplaced confidence in trial results and ignored data suggesting primary endpoint might not be met.
PICS · Capital · Negative Allegedly IPO offering documents failed to disclose deficient credit evaluation procedures and reclassification leading to expected credit loss charge.
VRRM · Demand · Negative Allegedly growth outlook dependent on a contract extension with Avis Budget while minimizing risks of replacement.
Grail Stock Crashed 50% After Mixed Trial Results, Then Partially Recovered
Grail stock plunged more than 50% in February after its landmark NHS-Galleri trial failed to meet the primary endpoint of a statistically significant reduction in late-stage cancer detection, though a favorable trend was seen in a pre-specified group of 12 deadly cancers. The multi-cancer early detection test Galleri is already available as a Laboratory Developed Test and can be purchased out of pocket, but the real catalyst for the stock will be FDA approval and subsequent adoption by insurers including Medicare. Management is working to release more detailed trial data and negotiate a 12-month follow-up to potentially prove the test's value, while emphasizing Galleri's higher sensitivity for the 12 deadly cancers. Insurers will ultimately need to weigh the cost-effectiveness of catching these cancers early against the expense of the test and follow-up procedures for false positives. Early investors Jeff Bezos and Bill Gates backed Grail before it was bought by Illumina in 2021 and spun off in 2024.
Rosen Law Firm reminds GRAIL investors of August 4 lead plaintiff deadline in securities class action
Rosen Law Firm reminds purchasers of GRAIL common stock between May 13, 2025 and February 19, 2026 of the August 4, 2026 lead plaintiff deadline in a securities class action. The lawsuit alleges that defendants made materially false and misleading statements and concealed adverse facts about the NHS-Galleri trial, including that the trial period was insufficient to demonstrate a reduction in Stage III-IV cancers and that detailed topline results were withheld. Investors who purchased shares during the class period may be entitled to compensation through a contingency fee arrangement without out-of-pocket costs. A lead plaintiff must move the Court by August 4, 2026.
Faruqi & Faruqi Reminds Grail Investors of August 4, 2026 Securities Class Action Deadline
Faruqi & Faruqi, LLP reminds investors of the August 4, 2026 deadline to seek lead plaintiff in a securities class action against Grail, Inc. The lawsuit alleges that Grail and its executives made false and misleading statements about the likelihood of success of its NHS-Galleri cancer detection trial, touting confidence in its effectiveness while concealing that the trial period was likely insufficient to achieve the primary endpoint of a statistically significant reduction in Stage III and IV cancers. On February 19, 2026, Grail announced the primary endpoint was not observed, causing its stock price to fall from $101.53 to $50.21 per share, a decline of about 50.55% in a single day. Investors who purchased or acquired Grail securities between May 13, 2025 and February 19, 2026 may be eligible to participate.
GRAIL faces securities fraud class action after NHS-Galleri trial misses primary endpoint
A securities fraud class action has been filed against GRAIL, Inc. and certain senior executives following a 50.55% stock drop on February 20, 2026. The lawsuit, pending in the U.S. District Court for the Northern District of California, alleges that GRAIL made misleading positive statements about its NHS-Galleri cancer screening trial, including that the three-year trial design was sufficient to achieve the primary endpoint of reducing late-stage cancers. On February 19, 2026, GRAIL disclosed that the trial did not meet that endpoint, attributing the shortfall partly to a need for longer follow-up, which caused shares to fall from $101.53 to $50.21. Investors have until August 4, 2026 to seek lead plaintiff appointment.
Holzer & Holzer Announces Lead Plaintiff Deadlines for Badger Meter, Grail, and PicS Class Actions
Holzer & Holzer reminds investors of upcoming lead plaintiff deadlines in shareholder class action lawsuits against Badger Meter, Grail, and PicS. The Badger Meter suit, covering purchases between April 18, 2024 and April 16, 2026, has a deadline of August 3, 2026. The Grail case, for shares bought from May 13, 2025 to February 19, 2026, and the PicS case, related to its January 2026 IPO, both have an August 4, 2026 deadline. Investors who suffered losses are encouraged to contact the firm.
Frank R. Cruz Law Offices Reminds Investors of Class Action Deadlines for BMI, PICS, VRRM, and GRAL
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of Badger Meter, PicS, Verra Mobility, and Grail, with lead plaintiff deadlines approaching. For Badger Meter, the class period is April 18, 2024 to April 16, 2026, and the lead plaintiff deadline is July 27, 2026; the complaint alleges the company pulled forward customer orders to recognize revenue early, concealing weakening demand. For PicS, the class period is January 27, 2026 to June 5, 2026, with a deadline of August 4, 2026; the complaint alleges the offering documents misrepresented credit evaluation procedures and failed to disclose a heightened Stage 3 formation rate and other risks. For Verra Mobility, the class period is February 24, 2026 to May 26, 2026, and the deadline is August 4, 2026; the complaint alleges the company's growth plans were dependent on a contract extension with Avis Budget and that it minimized risks of replacement. For Grail, the class period is May 13, 2025 to February 19, 2026, with a deadline of August 4, 2026; the complaint alleges management's confidence in trial results ignored trendlines suggesting the primary endpoint would be harder to achieve. Investors who suffered losses can contact the firm to discuss their legal rights.
Bernstein Liebhard announces securities class action against GRAIL, Inc.
Bernstein Liebhard LLP announced that a securities class action lawsuit has been filed against GRAIL, Inc. on behalf of investors who purchased or acquired GRAIL common stock between May 13, 2025 and February 19, 2026. The lawsuit alleges that defendants made materially false and misleading statements about the company's business operations, growth prospects, and financial stability, causing GRAIL stock to trade at artificially inflated prices. When the truth was disclosed, investors allegedly suffered significant losses. Investors have until August 4, 2026 to file papers to serve as lead plaintiff.
Grail Investors May Recover Losses Through Class Action, Robbins LLP Says
Robbins LLP reminds investors that a class action has been filed on behalf of purchasers of Grail, Inc. securities between May 13, 2025 and February 19, 2026. The lawsuit alleges that Grail misled investors about the likelihood of success for its NHS-Galleri trial in achieving a statistically significant reduction in late-stage cancers. On February 19, 2026, the company reported the trial failed to meet its primary endpoint, causing the stock to drop from $101.53 to $50.21 per share, a decline of approximately 50.55% in one day. Shareholders have until August 4, 2026 to seek lead plaintiff status, though participation is not required to be eligible for recovery. Robbins LLP is handling the case on a contingency fee basis.
Moore Law PLLC Encourages Grail, Inc. Investors to Contact Firm Over Potential Claims
Moore Law PLLC is investigating potential claims against the officers and directors of Grail, Inc. The investigation concerns allegations that the company or certain officers made false and misleading statements and failed to disclose material information, artificially inflating Grail’s stock price. On February 20, 2026, Grail’s shares fell from $101.53 to $50.21, a decline of approximately 50.55% in a single trading day, after the alleged misrepresentations became apparent. Shareholders who purchased Grail common stock during the class period may be able to seek monetary damages and other remedies at no cost, as representation is on a contingency fee basis. Investors are encouraged to contact Fletcher Moore at fletcher@fmoorelaw.com.
Grail's Galleri Cancer Test Misses Key Trial Endpoint but Still Eyes FDA Approval
Grail's multi-cancer early detection test Galleri missed its primary endpoint of reducing late-stage cancers in a 142,000-person NHS trial, but the company is still pursuing FDA approval and insurer coverage. CFO Aaron Freidin said 12-month follow-up data could show more cancers in the control group, supporting the test's benefit. The trial showed a favorable trend for 12 deadly cancers, with episode sensitivity of 54.7% versus 30.7% overall, and positive predictive values of 52% in the NHS study and 60.3% in the PATHFINDER 2 study. Management believes these metrics may encourage insurers to focus on the cost-benefit of detecting those 12 cancers.
Bronstein, Gewirtz & Grossman LLC Files Class Action Against GRAIL, Inc. Alleging Investor Harm
Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against GRAIL, Inc. and certain officers, alleging violations of federal securities laws. The suit covers investors who purchased or acquired Grail securities between May 13, 2025 and February 19, 2026. The complaint claims defendants misrepresented the likelihood of achieving the primary endpoint in the NHS-Galleri trial, overstated optimism about the study, and made misleading statements based on positive top-line results while ignoring contrary data trends. Investors have until August 4, 2026 to seek lead plaintiff appointment.
GRAL · Regulation · Negative Class action lawsuit alleging securities law violations for misrepresenting trial endpoint likelihood and misleading statements.
Grabar Law Office Investigates Claims for Long-Term Shareholders of Badger Meter, GeneDx, GRAIL, and Verra Mobility
Grabar Law Office is investigating claims on behalf of long-term shareholders of Badger Meter, GeneDx Holdings, GRAIL, and Verra Mobility, concerning whether certain officers and directors breached their fiduciary duties. For Badger Meter, a recently filed federal securities class action alleges that the company attributed strong financial performance to sustainable demand-driven growth while results were materially impacted by pull-forward of customer orders, masking weakening demand trends, and the truth emerged through disappointing quarterly announcements in 2025 and 2026 that caused significant stock declines. For GeneDx, a securities fraud class action alleges that executives made false statements about the Fabric acquisition improving financials and creating efficiencies, when they knew of significant problems in Fabric's viability that would negatively impact the business. For GRAIL, a complaint alleges that officers misled investors about the likelihood that the NHS-Galleri cancer screening trial would meet its primary endpoint, and the stock fell more than 50% in a single day after the company announced on February 19, 2026 that the trial failed to achieve a statistically significant reduction in late-stage cancers. For Verra Mobility, a class action alleges that executives created a false impression about revenue outlook and contract renewals while minimizing risks, and the stock declined approximately 71% after the company announced on May 26, 2026 that it received a termination notice from Avis Budget Group and lowered its full-year 2026 financial outlook. Shareholders who purchased or acquired shares prior to specified dates and still hold them can seek corporate reforms and return of funds at no cost.
BMI · Demand · Negative Allegations that strong financial performance was due to pull-forward of orders masking weakening demand, with disappointing quarterly announcements causing stock declines.
GRAL · Technology · Negative NHS-Galleri cancer screening trial failed to meet primary endpoint, causing stock to fall over 50% in one day.
VRRM · Demand · Negative Received termination notice from Avis Budget Group and lowered full-year 2026 financial outlook, causing stock to decline approximately 71%.
WGS · Capital · Negative Allegations that executives made false statements about Fabric acquisition improving financials and creating efficiencies, when they knew of significant problems in Fabric's viability.
USA